Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6974-6978

  Biggar, Robert J ^a   Johansen, Julia S ^b   Smedby, Karin Ekström ^c   Rostgaard, Klaus ^a   Chang, Ellen T ^e,f   Adami, Hans Olov ^d,g   Glimelius, Bengt ^d,h   Molin, Daniel ^h   Hamilton Dutoit, Stephen ⁱ   Melbye, Mads ^a   Hjalgrim, Henrik ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NORTHERN CALIFORNIA CANCER CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; PROTEIN YKL 40; UNCLASSIFIED DRUG; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; BLOOD; MIDDLE AGED;

ADULT; AGED; FEMALE; GLYCOPROTEINS; HODGKIN DISEASE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149241012     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1026     Document Type: Article

References (16)

1. Ma Y, van den Berg A, Atayar C, Visser L, Poppema S. Cytokines, cytokine receptors, and chemokines in Hodgkin lymphoma. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, editors. Hodgkin lymphoma. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 87-98.
2. Poppema S. Dysregulated immune response in Hodgkin lymphoma. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, editors. Hodgkin lymphoma. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 99-107.
3. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108:3786-91.
4. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price P. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202.
5. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209.
6. Dickey BF. Exoskeletons and exhalation. N Engl J Med 2007;357:2082-3.
7. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
8. Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10:345-50.
9. Aldinucci D, Lorenzon D, Olivo K, Rapanà B, Gattei V. Interactions between tissue fibroblasts inlymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004;45:1731-9.
10. Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004;103:3216-21.
11. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 2005;97:199-209.
12. Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007;67:2382-8.
13. Stein H, Delsol G, Pileri S, et al. Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 237-53.
14. Høgdall EVS, Johansen JS, Kjaer SK, et al. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000;60:247-52.
15. Knudsen LS, Christensen IJ, Lottenburger T, et al. Pre-analytical and biological variability in circulating IL-6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2008;13:59-78.
16. Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem 1998;44:509-16.